Blood test may shield cancer Patients' hearts from chemo damage

NCT ID NCT04737265

Completed Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined, stayed, and followed the medication plan. The goal was to see if this personalized approach is feasible and safe compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cardiomyopathy Cardiotoxicity chemotherapy-induced toxicity heart failure lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CARDIOMYOPATHIES CARDIOTOXICITY HEART FAILURE LYMPHOMA TOXICITY DUE TO CHEMOTHERAPY

Contacts and locations

Locations

Abramson Cancer Center at University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Chester County Hospital

West Chester, Pennsylvania, 19380, United States
City of Hope

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.